EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma

Lung Cancer. 2020 Jul;145:216-218. doi: 10.1016/j.lungcan.2020.04.001. Epub 2020 Apr 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Afatinib / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / genetics
  • Cyclin-Dependent Kinase 4 / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Piperazines
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines

Substances

  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridines
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • palbociclib